Kristi Rosa | Authors


Zenocutuzumab Shows Ability to Inhibit NRG1 Fusion–Positive Tumors

April 14, 2021

Zenocutuzumab has been shown to block the growth and cause the death of NRG1 fusion–positive cell lines, and to induce tumor shrinkage and durable tumor regression in multiple cancers when used in NRG1 fusion–positive patient-derived xenografts.

Sacituzumab Govitecan Prompts Clinical Benefit in Metastatic TNBC, Regardless of Trop-2 Expression

December 11, 2020

Sacituzumab govitecan (Trodelvy) induced clinical benefit over physician’s choice of therapy in patients with metastatic triple-negative breast cancer, irrespective of Trop-2 expression, though greater efficacy was observed in those who had a medium or high Trop-2 score.

Hematologic Cancers Bear Increased Risk for Adverse COVID-19 Outcomes

December 08, 2020

Patients with hematologic malignancies were found to be at increased risk for significant morbidity and mortality from COVID-19, and the risk of death appeared to be greatest in those who were older, had more severe infection, a poorer prognosis, or who decided to forego intensive treatment.